Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
02 Aug 2024
02 Aug 2024
Historique:
received:
21
02
2024
accepted:
22
07
2024
revised:
17
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
aheadofprint
Résumé
Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified metastasis-associated CNAs both in metastatic breast cancers (mBCs) and early breast cancers (eBCs). Single-nucleotide polymorphism (SNP)-array was performed on 926 biopsies from mBC patients, enrolled in SAFIR02-BREAST prospective trial. CNA profiles of eBCs from The Cancer Genome Atlas Breast Invasive Carcinoma (n = 770), Molecular Taxonomy of Breast Cancer International Consortium (n = 1620) and PACS04 trial (n = 243) cohorts were used as references for comparing mBCs and eBCs CNA profiles. Overall survival was the considered survival endpoint. Among the twenty-one genes frequently altered in ER + /HER2- mBCs: focal amplification of TERT was associated with poor outcome in the ER + /HER2- mBC population. Among the ER + /HER2- mBCs patients for whom CDK4/6 inhibitors information before biopsies collection was available: we identified seven genes on post-treatment biopsies, including the cyclin-dependent kinase 4 (CDK4), which was amplified in 9.8% of the ER + /HER2- mBCs pretreated population, as compared to 1.5% in the ER + /HER2- mBCs unpretreated population (P = 2.82E-04) as well as the 3 eBC populations. CDK4 amplification was associated with poor outcome in the ER + /HER2- eBCs. This study provides insights into the biology of mBCs and identifies clinically useful genomic features for future improvement of breast cancer patient management.
Sections du résumé
BACKGROUND
BACKGROUND
Copy number alterations (CNA) are acquired during the evolution of cancers from their early stage to metastatic stage. This study aims at analysing the clinical value of the identified metastasis-associated CNAs both in metastatic breast cancers (mBCs) and early breast cancers (eBCs).
METHODS
METHODS
Single-nucleotide polymorphism (SNP)-array was performed on 926 biopsies from mBC patients, enrolled in SAFIR02-BREAST prospective trial. CNA profiles of eBCs from The Cancer Genome Atlas Breast Invasive Carcinoma (n = 770), Molecular Taxonomy of Breast Cancer International Consortium (n = 1620) and PACS04 trial (n = 243) cohorts were used as references for comparing mBCs and eBCs CNA profiles. Overall survival was the considered survival endpoint.
RESULTS
RESULTS
Among the twenty-one genes frequently altered in ER + /HER2- mBCs: focal amplification of TERT was associated with poor outcome in the ER + /HER2- mBC population. Among the ER + /HER2- mBCs patients for whom CDK4/6 inhibitors information before biopsies collection was available: we identified seven genes on post-treatment biopsies, including the cyclin-dependent kinase 4 (CDK4), which was amplified in 9.8% of the ER + /HER2- mBCs pretreated population, as compared to 1.5% in the ER + /HER2- mBCs unpretreated population (P = 2.82E-04) as well as the 3 eBC populations. CDK4 amplification was associated with poor outcome in the ER + /HER2- eBCs.
CONCLUSIONS
CONCLUSIONS
This study provides insights into the biology of mBCs and identifies clinically useful genomic features for future improvement of breast cancer patient management.
Identifiants
pubmed: 39090361
doi: 10.1038/s41416-024-02804-6
pii: 10.1038/s41416-024-02804-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-17-RHUS-0008
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-17-RHUS-0008
Organisme : Agence Nationale de la Recherche (French National Research Agency)
ID : ANR-17-RHUS-0008
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71:7–33.
doi: 10.3322/caac.21654
Riggio AI, Varley KE, Welm AL. The lingering mysteries of metastatic recurrence in breast cancer. Br J Cancer. 2021;124:13–26.
doi: 10.1038/s41416-020-01161-4
pubmed: 33239679
Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7:791–9.
doi: 10.1038/nrc2212
pubmed: 17851544
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.
doi: 10.1073/pnas.191367098
pubmed: 11553815
pmcid: 58566
Thennavan A, Beca F, Xia Y, Garcia-Recio S, Allison K, Collins LC, et al. Molecular analysis of TCGA breast cancer histologic types. Cell Genomics. 2021;1:100067.
doi: 10.1016/j.xgen.2021.100067
pubmed: 35465400
pmcid: 9028992
McAndrew NP, Finn RS. Clinical review on the management of hormone receptor-positive metastatic breast cancer. JCO Oncol Pract. 2022;18:319–27.
doi: 10.1200/OP.21.00384
pubmed: 34637323
Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). JCO. 2020;38:3987–98.
doi: 10.1200/JCO.20.02514
Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, et al. Precision medicine for metastatic breast cancer—limitations and solutions. Nat Rev Clin Oncol. 2015;12:693–704.
doi: 10.1038/nrclinonc.2015.123
pubmed: 26196250
Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 2002;44:121–41.
doi: 10.1016/S1040-8428(01)00191-3
pubmed: 12413631
Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat Commun. 2017;8:14944.
doi: 10.1038/ncomms14944
pubmed: 28429735
pmcid: 5474888
Schrijver WAME, Selenica P, Lee JY, Ng CKY, Burke KA, Piscuoglio S, et al. Mutation profiling of key cancer genes in primary breast cancers and their distant metastases. Cancer Res. 2018;78:3112–21.
doi: 10.1158/0008-5472.CAN-17-2310
pubmed: 29615433
pmcid: 6355142
Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34:427–438.e6.
doi: 10.1016/j.ccell.2018.08.008
pubmed: 30205045
pmcid: 6327853
Callens C, Driouch K, Boulai A, Tariq Z, Comte A, Berger F, et al. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study. Genome Med. 2021;13:44.
doi: 10.1186/s13073-021-00862-6
pubmed: 33722295
pmcid: 7962302
Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria JC, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13:e1002201.
doi: 10.1371/journal.pmed.1002201
pubmed: 28027327
pmcid: 5189935
Angus L, Smid M, Wilting SM, van Riet J, Van Hoeck A, Nguyen L, et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat Genet. 2019;51:1450–8.
doi: 10.1038/s41588-019-0507-7
pubmed: 31570896
pmcid: 6858873
Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560–4.
doi: 10.1038/s41586-019-1056-z
pubmed: 31118521
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, et al. Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022;610:343–8.
doi: 10.1038/s41586-022-05068-3
pubmed: 36071165
Bachelot T, Filleron T, Bieche I, Arnedos M, Campone M, Dalenc F, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021;27:250–5.
doi: 10.1038/s41591-020-01189-2
pubmed: 33462450
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
doi: 10.1038/nature10983
pubmed: 22522925
pmcid: 3440846
Bieche I, Parfait B, Le Doussal V, Olivi M, Rio MC, Lidereau R, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res. 2001;61:1652–8.
pubmed: 11245479
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47–54.
doi: 10.1038/nature17676
pubmed: 27135926
pmcid: 4910866
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–5.
doi: 10.1126/science.7605428
pubmed: 7605428
Poremba C, Scheel C, Hero B, Christiansen H, Schaefer KL, Nakayama Jichi, et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: a molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. JCO. 2000;18:2582–92.
doi: 10.1200/JCO.2000.18.13.2582
Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49:349–57.
doi: 10.1038/ng.3781
pubmed: 28135248
pmcid: 5571729
Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, et al. TERT promoter hotspot mutations in breast cancer. Breast Cancer. 2018;25:292–6.
doi: 10.1007/s12282-017-0825-5
pubmed: 29222734
Gay-Bellile M, Véronèse L, Combes P, Eymard-Pierre E, Kwiatkowski F, Dauplat MM, et al. TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer. Oncotarget. 2017;8:77540–51.
doi: 10.18632/oncotarget.20560
pubmed: 29100407
pmcid: 5652798
Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21:220–4.
doi: 10.1038/6010
pubmed: 9988278
McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, et al. Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice. Front Oncol. 2019;9:666.
doi: 10.3389/fonc.2019.00666
pubmed: 31396487
pmcid: 6664013
Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv Cancer Res. 2013;119:191–419.
Saba R, Alsayed A, Zacny JP, Dudek AZ. The role of forkhead box protein M1 in breast cancer progression and resistance to therapy. Int J Breast Cancer. 2016;2016:1–8.
doi: 10.1155/2016/9768183
Ziegler Y, Laws MJ, Sanabria Guillen V, Kim SH, Dey P, Smith BP, et al. Suppression of FOXM1 activities and breast cancer growth in vitro and in vivo by a new class of compounds. NPJ Breast Cancer. 2019;5:45.
doi: 10.1038/s41523-019-0141-7
pubmed: 31815181
pmcid: 6884575
Guillen VS, Ziegler Y, Gopinath C, Kumar S, Dey P, Plotner BN, et al. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs. Breast Cancer Res Treat. 2023;198:607–21.
doi: 10.1007/s10549-023-06878-3
pubmed: 36847915